. 2023 Oct 26;15(11):2535. doi: 10.3390/pharmaceutics15112535
© 2023 by the authors.
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Figure 1.
TKIs currently approved for CML treatment.